Organon & Co. (BMV:OGN)

Mexico flag Mexico · Delayed Price · Currency is MXN
150.00
0.00 (0.00%)
Last updated: May 29, 2025
-57.87%
Market Cap 47.28B
Revenue (ttm) 128.64B
Net Income (ttm) 15.33B
Shares Out n/a
EPS (ttm) 58.81
PE Ratio 3.08
Forward PE 2.48
Dividend 17.03 (11.35%)
Ex-Dividend Date May 12, 2025
Volume n/a
Average Volume 1,163
Open 150.00
Previous Close 150.00
Day's Range 150.00 - 150.00
52-Week Range 150.00 - 426.40
Beta n/a
RSI 4.64
Earnings Date Aug 7, 2025

About Organon & Co.

Organon & Co. develops and delivers health solutions through prescription therapies and medical devices in the United States, Europe, Canada, Japan, rest of the Asia Pacific, Latin America, the Middle East, Russia, Africa, and internationally. The company's women’s health portfolio comprises contraception and fertility brands, such as Nexplanon, a long-acting reversible contraceptive; NuvaRing, a monthly vaginal contraceptive ring; Cerazette, Marvelon, and Mercilon, which are daily pills used to prevent pregnancy; Follistim AQ, which is used to... [Read more]

Industry Pharmaceutical Preparations
Founded 1923
Employees 10,000
Stock Exchange Mexican Stock Exchange
Ticker Symbol OGN
Full Company Profile

Financial Performance

In 2024, Organon & Co.'s revenue was $6.40 billion, an increase of 2.24% compared to the previous year's $6.26 billion. Earnings were $864.00 million, a decrease of -15.54%.

Financial numbers in USD Financial Statements

News

There is no news available yet.